Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $744,377.40 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 220,230 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $3.38, for a total value of $744,377.40. Following the transaction, the chief executive officer now directly owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. This represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Checkpoint Therapeutics Price Performance

Shares of Checkpoint Therapeutics stock opened at $3.75 on Monday. Checkpoint Therapeutics, Inc. has a one year low of $1.38 and a one year high of $4.50. The business’s 50 day simple moving average is $3.59 and its two-hundred day simple moving average is $2.72. The stock has a market capitalization of $183.12 million, a P/E ratio of -2.04 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Sell-side analysts expect that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on CKPT. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital boosted their price target on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 16th.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CKPT. Magnus Financial Group LLC increased its holdings in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 4,000 shares during the period. Choreo LLC increased its stake in shares of Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after buying an additional 7,080 shares during the period. PVG Asset Management Corp raised its holdings in shares of Checkpoint Therapeutics by 9.2% during the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after acquiring an additional 12,676 shares in the last quarter. Virtu Financial LLC purchased a new stake in Checkpoint Therapeutics in the third quarter worth $30,000. Finally, XTX Topco Ltd bought a new stake in Checkpoint Therapeutics in the second quarter valued at $34,000. 22.00% of the stock is owned by institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.